Avivagen Press Release Correction

gbaf1news

Avivagen Inc. (TSXV:VIV) (Avivagen or the Company), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, would like to correct an error in the press release issued by the Company on April 9, 2019. The number of broker warrants (the Broker Warrants) issued in connection with the completion of the final tranche private placement of debentures and shares was 7,862 Broker Warrants rather than the 6,840 Broker Warrants referred to in the Companys previous press release. This correction does not change any other amounts or information reported in the April 9, 2019 press release.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta„¢ Technology and OxC-beta„¢ Livestock

Avivagens OxC-beta„¢ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta„¢ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta„¢ Livestock is currently registered and available for sale in the United States, Philippines, Taiwan, New Zealand and Thailand.

Avivagens OxC-beta„¢ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta„¢ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Vivamune„¢ Health Chews (Vivamune„¢)

Vivamune„¢ is an all-in-one chew that can dramatically simplify a pets supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta„¢, Vivamune„¢ targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune„¢ is available for sale in the United States, Canada, Philippines and Taiwan. For more information, visit www.vivamunehealth.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim, anticipate, appear, believe, consider, could, estimate, expect, if, intend, goal, hope, likely, may, plan, possibly, potentially, pursue, seem, should, whether, will, would and similar expressions. Statements about OxC-betas ability to replace antibiotics commonly added to livestock feeds or to fulfill the global mandate to remove in-feed antibiotics as growth promoters set out in this news release are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagens products may not gain market acceptance or regulatory approvals necessary to fulfill the global mandate to remove in-feed antibiotics as growth promoters. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright 2019 Avivagen Inc. OxC-beta„¢ is a trademark of Avivagen Inc.

Avivagen Inc.
Drew Basek
Director of Investor Relations
100
Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail:
[email protected]

Kym Anthony
Interim Chief Executive Officer
100 Sussex Drive,
Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website:
www.avivagen.com